Biolase (BIOL) Misses Q3 EPS by 5c, to Explore M&A
Tweet Send to a Friend
Biolase Technology, Inc. (NASDAQ: BIOL) reported Q3 EPS of ($0.10), $0.05 worse than the analyst estimate of ($0.05). Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
